Cell Source, Inc. (CLCS)
USD 0.28
(-16.67%)
USD 0.28
(-16.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.32 Million USD | -3.59% |
| 2022 | -4.17 Million USD | -3.9% |
| 2021 | -4.01 Million USD | -10.46% |
| 2020 | -3.63 Million USD | 4.39% |
| 2019 | -3.8 Million USD | -89.68% |
| 2018 | -2 Million USD | 12.5% |
| 2017 | -2.29 Million USD | 1.11% |
| 2016 | -2.31 Million USD | 0.08% |
| 2015 | -2.32 Million USD | 42.77% |
| 2014 | -4.05 Million USD | -15722.14% |
| 2013 | -25.62 Thousand USD | -1437.52% |
| 2012 | -1666.78 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.13 Million USD | -31.37% |
| 2024 Q2 | -1.19 Million USD | -4.88% |
| 2023 Q3 | -995.38 Thousand USD | -9.93% |
| 2023 FY | -4.18 Million USD | -0.18% |
| 2023 Q4 | -866.35 Thousand USD | 12.96% |
| 2023 Q1 | -1.41 Million USD | -31.96% |
| 2023 Q2 | -905.46 Thousand USD | 36.03% |
| 2022 Q2 | -1.03 Million USD | 1.79% |
| 2022 FY | -4.17 Million USD | -3.9% |
| 2022 Q3 | -1.01 Million USD | 1.72% |
| 2022 Q1 | -1.05 Million USD | -79.4% |
| 2022 Q4 | -1.07 Million USD | -5.58% |
| 2021 Q4 | -586.78 Thousand USD | 55.39% |
| 2021 FY | -4.01 Million USD | -10.46% |
| 2021 Q2 | -995.09 Thousand USD | 11.26% |
| 2021 Q3 | -1.31 Million USD | -32.18% |
| 2021 Q1 | -1.12 Million USD | -34.18% |
| 2020 Q4 | -835.72 Thousand USD | 28.3% |
| 2020 Q1 | -733.33 Thousand USD | -56.84% |
| 2020 Q2 | -903.33 Thousand USD | -23.18% |
| 2020 FY | -3.63 Million USD | 4.39% |
| 2020 Q3 | -1.16 Million USD | -29.04% |
| 2019 FY | -3.8 Million USD | -89.68% |
| 2019 Q1 | -1.17 Million USD | -170.15% |
| 2019 Q2 | -729.9 Thousand USD | 37.67% |
| 2019 Q3 | -1.43 Million USD | -96.83% |
| 2019 Q4 | -467.56 Thousand USD | 67.46% |
| 2018 Q2 | -423.9 Thousand USD | 35.78% |
| 2018 FY | -2 Million USD | 12.5% |
| 2018 Q4 | -433.47 Thousand USD | 11.29% |
| 2018 Q3 | -488.64 Thousand USD | -15.27% |
| 2018 Q1 | -660.11 Thousand USD | -8.67% |
| 2017 Q1 | -483.59 Thousand USD | 10.78% |
| 2017 Q3 | -555.13 Thousand USD | 14.15% |
| 2017 Q2 | -646.62 Thousand USD | -33.71% |
| 2017 FY | -2.29 Million USD | 1.11% |
| 2017 Q4 | -607.44 Thousand USD | -9.42% |
| 2016 Q1 | -644.67 Thousand USD | -4.43% |
| 2016 Q2 | -530.16 Thousand USD | 17.76% |
| 2016 FY | -2.31 Million USD | 0.08% |
| 2016 Q3 | -601.73 Thousand USD | -13.5% |
| 2016 Q4 | -542.02 Thousand USD | 9.92% |
| 2015 FY | -2.32 Million USD | 42.77% |
| 2015 Q4 | -617.34 Thousand USD | -12.42% |
| 2015 Q3 | -549.13 Thousand USD | 3.28% |
| 2015 Q1 | -587.74 Thousand USD | 62.07% |
| 2015 Q2 | -567.73 Thousand USD | 3.4% |
| 2014 Q1 | -11.89 Thousand USD | 29.07% |
| 2014 Q3 | -715.29 Thousand USD | 29.68% |
| 2014 Q2 | -1.01 Million USD | -8449.15% |
| 2014 FY | -4.05 Million USD | -15722.14% |
| 2014 Q4 | -1.54 Million USD | -116.63% |
| 2013 Q4 | -16.77 Thousand USD | -614.4% |
| 2013 Q3 | -2348.00 USD | 99.53% |
| 2013 Q2 | -496.28 Thousand USD | -10209.29% |
| 2013 FY | -25.62 Thousand USD | -1437.52% |
| 2013 Q1 | -4814.00 USD | 0.0% |
| 2012 FY | -1666.78 USD | 0.0% |
| 2012 Q3 | -24.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -223.891% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 14.256% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 75.764% |
| Nascent Biotech, Inc. | -2.22 Million USD | -93.972% |
| Rebus Holdings, Inc. | -664 Thousand USD | -551.408% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.284% |
| Qrons Inc. | -643.67 Thousand USD | -571.975% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1010.287% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 92.208% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -941.05% |
| Skye Bioscience, Inc. | -13.67 Million USD | 68.363% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 93.975% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 188.006% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1552.624% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.296% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -51.74% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -181.589% |
| Mesoblast Limited | -84.14 Million USD | 94.86% |
| Marizyme, Inc. | -34.08 Million USD | 87.311% |
| Genus plc | 6.4 Million USD | 167.584% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 144.397% |
| Pharming Group N.V. | -4.87 Million USD | 11.358% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -117.739% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -364.402% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 48.199% |
| ContraFect Corporation | -56.88 Million USD | 92.397% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 5.036% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -208.515% |
| IMV Inc. | -38.67 Million USD | 88.815% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -57.237% |
| MultiCell Technologies, Inc. | -722.81 USD | -598307.05% |
| ONE Bio Corp. | 13.68 Million USD | 131.614% |
| Accustem Sciences Inc. | -3.74 Million USD | -15.453% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 92.668% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -795.402% |
| Q BioMed Inc. | -3.44 Million USD | -25.532% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 222.185% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -64.617% |
| Biomind Labs Inc. | -1 Million USD | -328.42% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 92.132% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -49.086% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 34.938% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -132.0% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -14340.925% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 72.745% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -123.809% |
| GB Sciences, Inc. | -1.42 Million USD | -204.493% |
| Alpha Cognition Inc. | -9.7 Million USD | 55.435% |
| HST Global, Inc. | -140.9 Thousand USD | -2969.646% |
| CSL Limited | 3.7 Billion USD | 100.117% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -284.507% |
| Halberd Corporation | -75.05 Thousand USD | -5663.286% |
| Enzolytics Inc. | -2.14 Million USD | -101.291% |
| Agentix Corp. | -1.37 Million USD | -215.315% |
| Resverlogix Corp. | -12.74 Million USD | 66.073% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -36.521% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.982% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -314.305% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -48.156% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -173.868% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -27.03% |
| AVAX Technologies, Inc. | 6.69 Million USD | 164.626% |
| Zenith Capital Corp. | -8.94 Million USD | 51.634% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.96% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -24728.345% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -76.162% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2421.927% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -115.754% |
| Kadimastem Ltd | -3.04 Million USD | -42.269% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -339.544% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -244.375% |
| BioStem Technologies, Inc. | -7.77 Million USD | 44.397% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2283.308% |
| LadRx Corporation | -3.82 Million USD | -13.122% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -529.645% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -529.645% |
| NovAccess Global Inc. | -2.46 Million USD | -75.345% |
| Affymax, Inc. | -15.04 Million USD | 71.253% |
| Itoco Inc. | -919.14 Thousand USD | -370.586% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2.051% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -286.537% |
| Mobile Lads Corp. | -554.55 Thousand USD | -679.974% |
| CytoDyn Inc. | -18.05 Million USD | 76.047% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -17084.529% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1865.37% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -665.923% |
| SYBLEU INC | -149.18 Thousand USD | -2799.414% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -138.138% |
| International Stem Cell Corporation | -663 Thousand USD | -552.39% |
| Bioxytran, Inc. | -3.82 Million USD | -13.225% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8116.843% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -21165.221% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 88.073% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -167.327% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -487.815% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -39.034% |
| Neutra Corp. | -229.48 Thousand USD | -1784.797% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 75.339% |
| PureTech Health plc | -146.19 Million USD | 97.041% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 79.874% |
| IXICO plc | -1.43 Million USD | -200.998% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 54.427% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.449% |
| CSL Limited | 3.81 Billion USD | 100.113% |
| Cellectis S.A. | -108.85 Million USD | 96.027% |